Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Schizophrenia
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Schizophrenia
    Schizophrenia and Bipolar Disorder Share Genetic Roots, Researchers Find - (DGNews)
    Long-Acting Risperidone Shows Benefits in Recent-Onset Schizophrenia: Presented at WCBP - (DGDispatch)
    Injectable Risperidone Superior to Oral Quetiapine in Stable Patients With Schizophrenia Who Need Treatment Switch: Presented at WCBP - (DGDispatch)
    TopAbstracts in Schizophrenia 06/25/2009 - (DGNews)
    TopAbstracts in Schizophrenia 06/11/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Schizophrenia
    • Major Depression and Psychoses: Screening, Accurately Diagnosing, and Properly Managing in Primary Care
    • Consistent Approach and Assessment Tools Aid Screening for Major Depressive Disorder and Psychosis in Primary Care
    • Navigating Differential Diagnosis in Major Depressive Disorder: The Role of the Primary Care Physician
    • Newer Classes Enhance Traditional Antidepressants and Are Preferred First-Line Therapies in Primary Care
    • Optimizing the Management of Schizophrenia: Evidence-Based Methods to Minimize the Burden of Disease in Managed Care

      Webcasts/CME archive

       Recent cases - Schizophrenia
        Localisation Using Mini C-Arm Fluoroscopy of Needles Ingested by a Woman with Schizophrenia: A Case Report
        Schizophrenia Spectrum Disorders in a Nigerian Family: 4 Case Reports
        Massive Pulmonary Emboli Associated with Olanzapine
        Presentation and Course of Brain Metastases from Breast Cancer in a Paranoid-Schizophrenic Patient: A Case Report
        Diabetic Control and Atypical Antipsychotics: A Case Report

        Cases archive
          




        my personal edition > schizophrenia > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        Comparative Efficacy and Safety of Ziprasidone and Clozapine in Treatment-Refractory Schizophrenia: Presented at APA

        TORONTO, CANADA -- May 26, 2006 -- Ziprasidone and clozapine show equivalent improvement in treatment-resistant/intolerant patients with schizophrenia, according to results of an 18-week, double-blind study.

        Results from Monitoring Oral Ziprasidone as Rescue Therapy in Neuroleptic-Resistant/Intolerant Patients (MOZART) were presented here on May 23rd at the 159th Annual Meeting of the American Psychiatric Association (APA).

        The study involved patients who had failed previous antipsychotic therapy. At least 20% of schizophrenia patients do not respond to antipsychotic treatment, investigators said.

        While clozapine is effective for treatment of schizophrenia, it is usually reserved for patients who are unresponsive to previous therapies because of its potential for significant adverse events, said investigator Emilio Sacchetti, MD, chair of psychiatry, Brescia University School of Medicine, and head, department of mental health, Brescia Spedali Civili, Brescia, Italy.

        "Effective treatment options that are well tolerated are much needed in this population at every stage of treatment," Dr. Sacchetti said.

        Study subjects who were enrolled in the study met criteria for treatment resistance, which was defined as nonresponse in 3 or more adequate antipsychotic trials in the past 5 years or inability to tolerate antipsychotic treatment.

        Poor treatment response with prior therapy was cited by the majority of patients enrolled in the study (ziprasidone, 80%; clozapine, 89%). The four most common antipsychotic treatments patients had been receiving at the study screening were haloperidol, olanzapine, risperidone and quetiapine.

        Patients were randomized to ziprasidone 80 to 160 mg/day (n=73) or clozapine 250 to 600 mg/day (n=74). The average ziprasidone dose during the study was 130.4 mg/day, and the average clozapine dose was 345.7 mg/day.

        Both ziprasidone and clozapine were associated with significant reductions in total score from baseline in the Positive and Negative Syndrome Scale (PANSS) from day 11 through study endpoint. Both drugs were also associated with significant reductions in the Clinical Global Impression - Severity (CGI-S) score from day 11 for ziprasidone and day 18 for clozapine to study endpoint.

        Both drugs were also associated with significant improvement from baseline in depressive symptoms (P <.001). Decreases in the Calgary Depression Scale for Schizophrenia were 3.1 for ziprasidone and 2.1 for clozapine.

        Ziprasidone, compared to clozapine, were both associated with significant reductions in median cholesterol levels (-5 versus +2 mg/dL), low-density lipoprotein (LDL) cholesterol (-6 vs. +4 mg/dL) and triglycerides (-15 vs. +10 mg/dL), with no change in fasting glucose (0 vs. +6 mg/dL) and body weight (-5.7 vs. +1.8 lbs.).

        Dr. Sacchetti said ziprasidone patients reported more insomnia than clozapine patients, while clozapine patients reported more salivation, somnolence and tachycardia.

        Overall, ziprasidone offers comparable efficacy but better tolerability than clozapine for patients who have failed prior antipsychotic therapy, he concluded.

        The results are consistent with previous studies that support the effectiveness of ziprasidone for schizophrenia patients who have failed previous antipsychotic treatments, he added.

        The study was sponsored by Pfizer in Italy.


        [Presentation title: Comparative Efficacy and Safety of Ziprasidone and Clozapine in Treatment-Refractory Schizophrenia: Results of a Randomized, Double-Blind, 18-Week Trial. Abstract NR425]



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send